Probable etoricoxib-induced fixed drug eruption involving the oral mucosa: A case report.

Autor: Perks A; Oral Medicine, Birmingham Dental Hospital and School of Dentistry, Birmingham, UK. Electronic address: A.c.perks@bham.ac.uk., Bates TJ; Oral Pathology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Velangi S; Dermatology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Brown RM; Oral Pathology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK., Poveda-Gallego A; Oral Medicine, Birmingham Dental Hospital and School of Dentistry, Birmingham, UK.
Jazyk: angličtina
Zdroj: Oral surgery, oral medicine, oral pathology and oral radiology [Oral Surg Oral Med Oral Pathol Oral Radiol] 2021 Apr; Vol. 131 (4), pp. e100-e107. Date of Electronic Publication: 2020 Dec 26.
DOI: 10.1016/j.oooo.2020.12.019
Abstrakt: Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by recurrence of lesions at the same sites each time a specific drug is taken. Oral mucosal involvement is rare. Nonsteroidal anti-inflammatory drugs are one of the most common offending drug groups in FDE; however, selective cyclooxygenase-2 inhibitors, such as etoricoxib, are rarely implicated. We present a case of oral mucosal and cutaneous FDE induced by etoricoxib that, to the best of our knowledge, is the first reported case of this nature. We describe the diagnostic challenges and review the pertinent literature. The value of drug provocation testing and patch testing in FDE is also discussed.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: